Skip to main content

Adenovirus clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

    open to eligible people ages 1 month to 30 years

    Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD

    at UCSF

Last updated: